Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
SQ

NYSE · SQZ

SQZ Biotechnologies Company

Healthcare · Biotechnology

$0.44

Up+$0.17 (+61.11%)

Updated Aug 15, 2026, 4:59 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
12.83M
P/E ratio
-0.01
Dividend yield
0.00%
52-week range
— – —
Volume
30.14M
Avg. volume
669.93K

Price performance

SQZ price history

1M range · 0 trading sessions · Daily adjusted prices

SQZ does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest SQZ news

The latest Smart Investors Daily articles mentioning SQZ.

Stock researchCompany · Overview

SQZ research

Overview

Company profile and research snapshot.

Company profile

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
SQZ recent ratings
DateFirmRatingTarget
Dec 2, 2022HC Wainwright & Co.Neutral—
Dec 1, 2022Chardan CapitalBuy—
Dec 1, 2022B of A SecuritiesUnderperform—
Nov 10, 2022Chardan CapitalBuy—
Oct 20, 2022HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

defenseworld.net · Nov 25, 2025

Analyzing Genocea Biosciences (NASDAQ:GNCAQ) & SQZ Biotechnologies (NYSE:SQZ)

Earnings and Valuation This table compares SQZ Biotechnologies and Genocea Biosciences"s revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SQZ Biotechnologies $18.16 million 0.04 -$79.46 million ($2.61) -0.01 Genocea Biosciences N/A N/A N/A ($0.19) N/A Genocea Biosciences has lower revenue, but higher earnings than SQZ Biotechnologies.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By